Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

ALK – Financial calendar for the 2018 financial year


Posted on: 20 Dec 17

Copenhagen, 2017-12-20 11:06 CET (GLOBE NEWSWIRE) --    

2018 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF):

 

  • Silent period                                                   9 January 2018
  • Annual report 2017                                       6 February 2018
  • Annual General Meeting to be held                12 March 2018
    at ALK                                                                       4.00 p.m.
    Bøge Allé 1
    2970 Hørsholm, Denmark

    Written requests to have specific business
    transacted at the AGM will be included in the
    agenda if received by the company on
    26 January 2018 at the latest
    (may be e-mailed to investor@alk.net)
     
  • Silent period                                                        6 April 2018
  • Three-month interim report (Q1) 2018                 4 May 2018
  • Silent period                                                       18 July 2018
  • Six-month interim report (Q2) 2018               15 August 2018
  • Silent period                                                 12 October 2018
  • Nine-month interim report (Q3) 2018         9 November 2018
     

ALK-Abelló A/S 

 

For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014
 

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen. Find more information at www.alk.net.

GlobeNewswire
globenewswire.com

Last updated on: 20/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.